Drug Search Results

Gandotinib

Alternative Names: gandotinib, ly2784544
Latest Update: 2024-12-12
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: JAK2 Inhibitor,STAT3 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gandotinib

Countries in Clinic: Austria, Germany, Spain

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
I3X-MC-JHTB	P2	Unknown Status	Polycythemia Vera\|Myelofibrosis\|Thrombocythemia, Essential	2024-12-31

Recent News Events

Date	Type	Title
09/15/2023	PubMed	Kv1.3 mediates ox-LDL-induced vascular smooth muscle cell proliferation through JAK2/STAT3 signaling pathway.
11/15/2022	PubMed	Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors.
05/12/2020	News Article	Global Essential Thrombocythemia Market (2017 to 2030) - Insights, Epidemiology, and Market Forecast

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions